Market Outlook

By 2035, the U.S. Precision Oncology Devices Market is projected to reach approximately USD 35.71 billion, expanding at an estimated CAGR of 12.65% during the forecast period 2026–2035. The market is estimated at USD 10.85 billion in 2025, with historical analysis covering 2021–2024. Values throughout this report are expressed in USD billions.

For the purpose of this market assessment, precision oncology devices include next-generation sequencing and comprehensive genomic profiling systems, liquid biopsy and circulating tumor DNA platforms, PCR and digital PCR systems, companion diagnostic devices, immunohistochemistry and in situ hybridization platforms, digital pathology and AI-enabled diagnostic systems, molecular imaging platforms, image-guided tumor characterization technologies, biopsy-enabling systems, and device-linked software used to identify biomarkers, stratify patients, guide cancer therapy, monitor molecular response, or identify recurrence. The market excludes oncology pharmaceuticals and pure laboratory-service revenue where no meaningful device, platform, consumable, or regulated diagnostic technology component is involved.

The U.S. market is being fundamentally reshaped by the transition from organ-based oncology toward molecularly defined cancer management. Approximately 2.04 million new cancer cases were expected in the United States in 2025, creating a substantial addressable population for molecular profiling, pathology, imaging, liquid biopsy, companion diagnostics, and therapy-selection technologies. Lung, breast, colorectal, prostate, hematologic, and increasingly rare molecularly defined tumors represent particularly important testing pools because targeted therapies and biomarker-directed treatment algorithms are becoming more deeply embedded in oncology practice.

The commercial importance of precision oncology devices extends beyond the number of new cancer diagnoses. Patients may undergo testing at initial diagnosis, following progression, prior to changing systemic therapy, after surgery to evaluate molecular residual disease, or during longitudinal monitoring. The same patient can therefore generate multiple clinically distinct device-supported testing events across the disease journey. This recurring diagnostic intensity creates a different economic profile from conventional single-event cancer diagnostics.

The market expanded from approximately USD 6.92 billion in 2021 to USD 7.58 billion in 2022, USD 8.42 billion in 2023, USD 9.53 billion in 2024, and USD 10.85 billion in 2025. Historical expansion was supported by broader adoption of comprehensive genomic profiling, increasing use of liquid biopsy in advanced solid tumors, stronger companion diagnostic requirements, deployment of higher-throughput sequencing systems, digital pathology adoption, improved access to molecular testing, and increasing integration of genomic information into multidisciplinary tumor boards.

From 2026 through 2035, growth is expected to accelerate as precision oncology moves from testing selected advanced-stage patients toward a more longitudinal model incorporating diagnosis, therapy selection, resistance detection, recurrence surveillance, and selected screening applications. The largest economic opportunity will not necessarily belong to the company with the highest sequencing throughput. Competitive advantage will increasingly depend on delivering clinically actionable answers with reliable turnaround times, validated software, tissue-efficient workflows, reimbursement support, interoperable data, and evidence that the technology changes patient management.

The U.S. market is particularly attractive because it combines a large cancer population with sophisticated cancer centers, broad molecular laboratory infrastructure, high oncology drug spending, mature private and public reimbursement systems, extensive clinical trial activity, and a concentrated ecosystem of pharmaceutical, biotechnology, genomics, pathology, imaging, and artificial intelligence companies. By 2026, the country also had 74 NCI-Designated Cancer Centers across 37 states and the District of Columbia, reinforcing the institutional infrastructure through which novel precision-oncology technologies can be evaluated and disseminated.

The market should nevertheless be viewed as a clinically segmented opportunity rather than an unrestricted technology boom. Adoption will remain dependent on whether testing changes therapy, reduces diagnostic uncertainty, avoids ineffective treatment, preserves limited tissue, enables clinical-trial enrollment, or creates a credible surveillance pathway. Technologies that generate large volumes of data without improving actionable decision-making will face stronger procurement resistance as oncology programs become more disciplined about total diagnostic cost.

 

Introduction

According to the U.S. Precision Oncology Devices Market Report, precision oncology is evolving from a specialist genomic testing category into an integrated infrastructure layer across cancer diagnosis and treatment. Modern oncology increasingly requires clinicians to understand not only where a tumor originated but also the molecular alterations, protein expression patterns, immune characteristics, genomic instability, clonal evolution, and treatment-resistance mechanisms that influence the patient’s likely response.

This shift directly increases the strategic importance of devices capable of converting tissue, blood, cells, radiologic images, or pathology slides into actionable biological information.

The U.S. ecosystem is particularly well suited to this transition because large cancer programs increasingly operate multidisciplinary models involving medical oncology, pathology, radiology, radiation oncology, surgery, genetics, molecular laboratories, pharmacy, and clinical research. Precision oncology devices sit at the intersection of these functions. A tumor specimen may be collected through an image-guided biopsy, evaluated through digital pathology, analyzed using sequencing or molecular assays, interpreted through bioinformatics, and subsequently linked to an approved targeted therapy or clinical trial.

Regulatory activity demonstrates the pace of this shift. In 2024, U.S. regulators authorized 76 oncology-related devices, including 27 in vitro diagnostic devices and multiple new or expanded companion diagnostic indications. The following year, more than 90 oncology devices were authorized, showing that regulatory activity is extending across molecular diagnostics, radiology, artificial intelligence, treatment support, and related oncology technologies.

The market is also benefiting from increasingly sophisticated comprehensive genomic profiling. Modern systems can assess hundreds of genes and multiple biomarker classes in a single workflow. For example, recently approved tissue-based oncology profiling platforms can simultaneously interrogate hundreds of DNA targets together with RNA-based alterations. This reduces dependence on sequential single-gene testing and can preserve valuable tumor material, particularly in lung cancer and other cancers where biopsy specimens may be limited.

Hospital economics are consequently changing. Molecular oncology procurement is no longer evaluated only through instrument acquisition cost. Large systems compare sequencing throughput, reagent cost per sample, failed-run frequency, sample input requirements, turnaround time, staffing intensity, software licensing, data-storage expense, variant interpretation burden, reimbursement probability, and the cost of sending specimens to external laboratories.

This creates distinct strategic models. Some hospitals build high-volume internal molecular laboratories to control turnaround time and retain revenue. Others rely on reference laboratories because maintaining validated oncology panels, bioinformatics, quality systems, specialized staff, and regulatory compliance internally may not be economical. Hybrid models are becoming common, with high-frequency tests performed locally while complex or lower-volume assays remain outsourced.

A second structural shift is the growing importance of blood-based testing. Tissue remains essential to oncology diagnosis, but liquid biopsy is creating additional testing moments where tissue is unavailable, unsafe to obtain, insufficient, or clinically outdated. Plasma-based genomic profiling can help identify actionable alterations in advanced disease, characterize resistance, and potentially support longitudinal surveillance. The commercial significance lies not simply in substituting blood for tissue but in allowing molecular testing to be repeated more easily throughout the treatment pathway.

Digital pathology represents another important layer. Converting pathology slides into high-resolution digital images enables remote review, algorithm-assisted detection, quantitative biomarker assessment, workflow prioritization, research collaboration, and potentially more reproducible clinical interpretation. AI-enabled pathology will increasingly intersect with molecular testing as computational models combine morphology, protein expression, genomic data, and clinical variables.

The U.S. Precision Oncology Devices Market will therefore become progressively less defined by isolated instrument categories. The higher-value opportunity is an interconnected workflow capable of determining what tumor the patient has, which molecular characteristics matter, which therapy is most appropriate, whether the cancer is responding, and when biological evidence of recurrence appears.

 

Key Market Drivers: What’s Fueling the U.S. Precision Oncology Devices Market Boom?

The first structural driver is the scale and complexity of the U.S. cancer burden. Approximately 2.04 million new cancers and more than 618,000 cancer deaths were estimated for 2025. This creates a sustained clinical need for technologies that can detect disease, refine diagnosis, improve patient selection, reduce ineffective therapy, and monitor treatment response. Unlike conventional screening markets, precision oncology generates demand across multiple phases of the cancer journey.

A second driver is the increasing number of cancer therapies associated with specific biomarkers. Targeted therapies, biomarker-defined immunotherapies, antibody-drug conjugates, and molecularly restricted treatment indications create a direct requirement for reliable diagnostic information. Companion diagnostics therefore have a uniquely strong relationship with pharmaceutical innovation: every new actionable biomarker can generate an adjacent device opportunity.

The FDA’s precision oncology ecosystem has increasingly incorporated companion diagnostic development alongside drug approval. Biomarkers including EGFR, ALK, ROS1, BRAF, KRAS, HER2, IDH1/2, BRCA, PIK3CA, ESR1, MSI, tumor mutational burden, PD-L1, and numerous additional genomic or protein markers now influence therapeutic decisions across different malignancies. The commercial result is continued migration from sequential single-marker testing toward broader panels capable of supporting multiple potential therapeutic pathways.

A third driver is Medicare and commercial payer recognition of genomic testing in appropriately selected cancer patients. National Medicare coverage for qualifying next-generation sequencing tests in advanced cancer created an important reimbursement foundation for precision oncology. Reimbursement remains complex and varies by indication, test structure, coding pathway, laboratory status, and medical necessity, but coverage recognition has helped normalize comprehensive genomic testing within U.S. cancer care.

The fourth driver is the scarcity of tumor tissue. In lung, pancreatic, brain, metastatic, and other cancers, clinicians may have limited material available after diagnostic pathology. Running multiple sequential assays can exhaust specimens and require repeat biopsy. Multiplex NGS and integrated molecular platforms can conserve material by evaluating many biomarkers simultaneously. Tissue stewardship therefore has direct economic and patient-care value.

A fifth driver is the expansion of liquid biopsy. Blood-based tumor profiling provides a clinically attractive alternative when tissue biopsy is difficult or when clinicians need updated information after disease progression. Circulating tumor DNA platforms also create opportunities in molecular residual disease and recurrence monitoring. These applications potentially convert molecular testing from a one-time event into repeated longitudinal testing, increasing the lifetime diagnostic value associated with each oncology patient.

A sixth driver is the maturation of digital pathology. U.S. pathology departments face increasing case complexity while specialist capacity remains constrained. Digital slide systems can centralize workflow and enable remote interpretation, while artificial intelligence can support case prioritization, suspicious-region identification, quantitative assessment, and standardized biomarker measurement. The economic argument becomes stronger where digital pathology reduces slide transportation, enables subspecialist access across hospital networks, or improves pathologist productivity.

A seventh driver is pharmaceutical clinical development. Biomarker-driven oncology trials require technologies for patient identification, enrollment, stratification, pharmacodynamic assessment, and resistance monitoring. Pharmaceutical and biotechnology companies therefore represent an important non-provider customer group for sequencing platforms, biomarker assays, digital pathology, spatial biology, molecular imaging, and data interpretation systems.

Finally, U.S. health-system consolidation is influencing purchasing behavior. Large integrated delivery networks increasingly seek enterprise molecular diagnostics strategies rather than fragmented departmental purchasing. Vendors that can standardize workflows across multiple hospitals, integrate with laboratory information systems and electronic records, provide cybersecurity support, establish consistent quality metrics, and negotiate predictable reagent economics will be more defensible than vendors selling stand-alone instruments.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation within the U.S. Precision Oncology Devices Market is shifting from maximum data generation toward clinically efficient precision. Manufacturers are attempting to shorten the time between tissue acquisition and actionable treatment while increasing the amount of biological information obtained from limited specimens.

Comprehensive genomic profiling remains a major innovation area. In August 2024, an FDA-approved comprehensive oncology assay demonstrated the ability to evaluate 517 DNA genes and 25 RNA genes from tumor specimens. Another 2024-approved platform incorporated a 228-gene panel together with biomarkers such as microsatellite instability and tumor mutational burden. These approvals demonstrate how broad profiling systems are moving deeper into regulated clinical workflows.

Integrated sequencing is also improving laboratory economics. Newer systems increasingly automate nucleic-acid processing, sequencing, analysis, and reporting. The strategic objective is to reduce hands-on technician time and make molecular testing practical outside a small number of national reference laboratories. Faster sample-to-answer systems could increase adoption among regional academic hospitals and high-volume integrated cancer programs that currently send complex oncology testing externally.

Liquid biopsy is another innovation frontier. Blood-based tests can identify tumor-derived genetic material without requiring an invasive repeat biopsy. The FDA authorization of blood-based colorectal cancer screening technology in 2024 expanded the perceived commercial boundaries of circulating DNA beyond advanced cancer profiling. Although screening and treatment-selection applications have different clinical requirements, their convergence increases investment in high-sensitivity signal detection, methylation analysis, fragmentomics, and multimodal classifiers.

Minimal residual disease represents one of the most strategically important emerging categories. After apparently curative surgery or therapy, extremely small quantities of tumor-derived DNA may remain in circulation before recurrence is detectable radiographically. Technologies capable of identifying this signal could change surveillance pathways and potentially influence adjuvant treatment decisions. The opportunity is substantial because surveillance involves repeated testing rather than a single diagnostic event, although widespread adoption will depend heavily on prospective clinical utility evidence and reimbursement.

Digital pathology innovation is becoming more quantitative. AI algorithms are progressing beyond visual assistance toward cell counting, tumor-region detection, biomarker quantification, grading support, and prediction models. Pathology departments increasingly value systems that reduce repetitive work while retaining pathologist oversight. Longer term, computational pathology may identify image-based phenotypes associated with genomic mutations or therapy response, potentially allowing molecular and morphologic information to reinforce each other.

Molecular imaging is also becoming more precise. PET, CT, MRI, advanced ultrasound, radiomics, and targeted imaging agents can help define tumor biology, staging, therapy eligibility, and response. Precision oncology increasingly depends on combining molecular information with spatial information about where disease is located and how individual lesions behave. This creates opportunities for imaging companies capable of integrating acquisition, reconstruction, quantitative analysis, AI, and treatment-planning software.

Image-guided biopsy technology is similarly important because molecular testing is only as useful as the specimen entering the laboratory. Navigation, fusion imaging, robotic bronchoscopy, stereotactic guidance, interventional ultrasound, and improved biopsy devices can increase the likelihood that adequate viable tumor tissue is captured for downstream analysis.

Manufacturers are also raising the bar through workflow integration. Oncology programs increasingly prefer systems that connect specimen tracking, laboratory automation, digital pathology, genomic interpretation, therapeutic decision support, clinical-trial matching, and longitudinal patient data. The future commercial moat may therefore depend less on proprietary hardware alone and more on the installed ecosystem surrounding that hardware.

 

Segmentation Insights

The U.S. Precision Oncology Devices Market is segmented on the basis of product category, application, cancer type, end user, and region.

 

By Product Category

Comprehensive Genomic Profiling and NGS Platforms

Comprehensive genomic profiling and next-generation sequencing systems represent the largest product category, accounting for an estimated USD 3.67 billion, or approximately 33.8% of the 2025 market. This category includes sequencing instruments, oncology panels, integrated sequencing systems, library-preparation technologies, bioinformatics components, and device-linked consumables used for tumor profiling.

Demand is strongest in lung cancer, advanced solid tumors, hematologic malignancies, and cancers with multiple actionable molecular pathways. Broad panels can replace sequential testing, preserve specimens, and create opportunities for clinical-trial matching. Higher-throughput national laboratories favor platform scalability, whereas hospital laboratories increasingly value automation, shorter turnaround time, and simplified interpretation.

Liquid Biopsy and ctDNA Systems

Liquid biopsy platforms account for approximately USD 2.33 billion in 2025, representing one of the fastest-growing portions of the market. These systems analyze circulating tumor DNA, cell-free nucleic acids, circulating tumor cells, methylation signatures, or other blood-based cancer signals.

The segment is evolving across therapy selection, treatment-resistance detection, recurrence monitoring, and selected screening applications. Commercial growth could materially outpace the overall market because blood collection is easier to repeat than tissue biopsy. The most important constraints are sensitivity in low-shedding tumors, clinical utility requirements, false-positive management, and payer confidence in repeated testing.

PCR, Digital PCR and Targeted Molecular Systems

PCR and digital PCR technologies represent approximately USD 1.65 billion of the 2025 market. These technologies remain highly relevant when clinicians need rapid detection or highly sensitive measurement of known alterations rather than broad discovery.

Targeted molecular systems can offer lower cost, faster turnaround, simpler interpretation, and easier laboratory implementation than comprehensive sequencing. Digital PCR is particularly attractive for low-frequency variant detection and quantitative applications. Rather than being displaced by NGS, targeted platforms are likely to coexist with sequencing as laboratories align assay complexity with specific clinical questions.

Digital Pathology, IHC and ISH Platforms

Digital pathology, immunohistochemistry, in situ hybridization, slide scanning, image analysis, and related precision-pathology technologies represent approximately USD 1.48 billion in 2025. Protein expression and tissue architecture remain critical even as genomic testing expands.

PD-L1, HER2 and multiple other protein or gene-expression biomarkers continue to influence oncology treatment. Digital pathology adds the ability to centralize interpretation, apply quantitative algorithms, share cases across networks, and potentially integrate morphologic information with molecular data. Large academic health systems are likely to remain early adopters, followed progressively by community networks seeking enterprise pathology standardization.

Precision Imaging and Image-Guided Oncology Devices

Precision imaging and image-guided diagnostic technologies account for approximately USD 1.72 billion in 2025. The category includes oncology-focused molecular imaging systems, quantitative imaging software, advanced tumor characterization technologies, navigation systems, biopsy-guidance platforms, and related device technologies that improve lesion localization or treatment planning.

Growth is being driven by the increasing importance of phenotypic and spatial information alongside molecular data. Imaging technologies are particularly important in prostate, lung, breast, brain, liver, and metastatic cancers where lesion detection and accurate tissue acquisition directly influence downstream molecular testing.

 

By Application

Companion Diagnostics and Therapy Selection

Therapy selection represents the largest application, accounting for an estimated USD 4.12 billion in 2025. The segment benefits directly from the expansion of targeted treatments and biomarker-defined immunotherapies.

Its commercial strength comes from high clinical consequence. When an approved treatment requires or strongly depends on a biomarker result, testing becomes embedded in the treatment pathway. Device suppliers with regulatory claims linked to multiple therapeutic products can therefore build substantial strategic value.

Early Detection and Risk Stratification

Early detection and molecular risk stratification represent approximately USD 1.95 billion in 2025. The category includes blood-based screening, molecular pathology, risk algorithms, imaging-AI systems, and other technologies intended to identify cancer or meaningful risk earlier.

Growth potential is substantial because screening addresses much larger populations than advanced cancer treatment. However, the evidence threshold is also higher. Technologies must demonstrate appropriate sensitivity, specificity, manageable downstream diagnostic burden, and practical integration into established screening programs.

Minimal Residual Disease and Recurrence Surveillance

MRD and recurrence monitoring account for approximately USD 1.52 billion in 2025 and are expected to be among the fastest-expanding applications through 2035.

The commercial model is attractive because patients can require serial testing after surgery or systemic therapy. Adoption is increasing particularly in colorectal, breast, bladder, and hematologic cancers, although clinical utility and payer policies remain uneven. Companies that demonstrate that molecular recurrence information changes treatment and improves outcomes could unlock a substantial recurring-revenue pool.

Treatment Response and Resistance Monitoring

Treatment monitoring represents an estimated USD 1.84 billion market in 2025. Tumors evolve under treatment pressure, and resistance mutations can emerge over time. Repeat molecular analysis can help identify these changes without relying exclusively on additional tissue procedures.

This category is especially relevant in metastatic lung cancer, breast cancer, prostate cancer, hematologic malignancies, and other molecularly targeted settings. Technologies offering rapid turnaround and strong low-frequency variant detection are positioned favorably.

Clinical Trial Enrollment and Biomarker Research

Clinical-trial and biomarker-development applications account for approximately USD 1.42 billion in 2025. Precision oncology trials increasingly require prospective molecular screening to identify relatively small patient populations carrying particular mutations or expression signatures.

Pharmaceutical companies therefore support demand for sequencing, pathology, imaging, spatial biology, and data-interpretation systems. Decentralized molecular screening and large real-world genomic datasets are also improving trial feasibility for rare molecular subgroups.

 

By Cancer Type

Lung Cancer

Lung cancer represents the largest cancer-specific precision oncology device opportunity, estimated at approximately USD 2.71 billion in 2025. Its leadership reflects the large number of clinically actionable alterations and the importance of conserving small biopsy specimens.

NGS, liquid biopsy, PD-L1 testing, digital pathology, advanced imaging, robotic bronchoscopy, and image-guided biopsy all participate in the lung cancer pathway. Continued expansion of targeted therapies should sustain above-average testing intensity.

Breast Cancer

Breast cancer accounts for approximately USD 2.17 billion in 2025. Precision workflows include HER2 assessment, hormone-receptor testing, genomic recurrence assays, germline testing, circulating DNA, advanced breast imaging, and increasingly detailed molecular characterization of metastatic disease.

Growth is being driven by more granular HER2 categories, PI3K/AKT-pathway testing, ESR1-related therapy selection, inherited-risk evaluation, and molecular monitoring.

Colorectal Cancer

Colorectal cancer represents approximately USD 1.63 billion in 2025. Testing may include RAS, BRAF, MSI or mismatch-repair assessment, HER2-related profiling, broad genomic analysis, liquid biopsy, and molecular recurrence surveillance.

The introduction of an FDA-approved blood-based colorectal screening device expanded industry attention toward non-invasive early detection. MRD is also commercially important because colorectal cancer has emerged as one of the leading solid-tumor applications for postoperative circulating DNA surveillance.

Prostate Cancer

Prostate cancer represents approximately USD 1.30 billion in 2025. Demand includes molecular imaging, genomic risk assessment, inherited mutation testing, tumor sequencing, digital pathology, MRI-guided diagnostic workflows, and biomarker-supported treatment selection.

Prostate-specific molecular imaging has materially increased the role of advanced imaging in disease localization and staging, creating a strong intersection between conventional device companies and precision-diagnostic technologies.

Hematologic Malignancies

Leukemia, lymphoma, myeloma and related hematologic malignancies account for approximately USD 1.41 billion in 2025. These diseases are highly dependent on flow cytometry, cytogenetics, PCR, sequencing, measurable residual disease technologies, and increasingly sophisticated molecular classification.

Testing intensity is high because disease management frequently requires repeated molecular assessment. High analytical sensitivity is particularly important in MRD and clonal monitoring.

Other Solid Tumors

Other malignancies collectively represent approximately USD 1.63 billion in 2025, including melanoma, ovarian, pancreatic, endometrial, brain, thyroid, bladder, kidney, liver, sarcoma, and rare cancers.

Tumor-agnostic treatment strategies increase the value of broad molecular profiling in these smaller cancer populations because actionable biomarkers can transcend the tissue of origin.

 

By End User

Hospitals and Comprehensive Cancer Centers

Hospitals, academic medical centers and comprehensive cancer programs represent approximately 41% of the market, equivalent to about USD 4.45 billion in 2025.

These institutions generate the largest concentration of complex oncology procedures and commonly operate molecular pathology laboratories, digital pathology infrastructure, advanced radiology, clinical trials, and multidisciplinary tumor boards. Procurement decisions emphasize clinical evidence, throughput, integration, quality assurance, reimbursement, and total episode economics.

Diagnostic and Reference Laboratories

Reference and specialty molecular laboratories account for approximately USD 3.04 billion in 2025. Their scale allows them to run large oncology panels, highly specialized assays, and national testing programs economically.

Reference laboratories remain particularly important for hospitals that cannot justify the fixed cost of complex molecular infrastructure. Their competitive priorities include sample logistics, payer contracting, turnaround time, test breadth, evidence generation, and physician-facing interpretation.

Community Oncology Networks

Community oncology practices and regional cancer networks represent approximately USD 1.30 billion in 2025 and are becoming strategically important as precision oncology moves beyond major academic centers.

These customers require simplified ordering, predictable reimbursement, rapid results, actionable reports, and access to molecular testing without maintaining complex laboratory infrastructure locally. Vendors that integrate testing with electronic oncology workflows and clinical-trial matching can differentiate strongly.

Pharmaceutical, Biotechnology and CRO Customers

Pharmaceutical, biotechnology and clinical research organizations represent approximately USD 1.19 billion in 2025. Their demand includes trial screening, companion diagnostic development, biomarker validation, translational research, central laboratory workflows, imaging endpoints, and treatment-response assessment.

This segment is expected to grow as oncology pipelines become increasingly biomarker-defined.

Academic and Translational Research Institutes

Academic and research users represent approximately USD 0.87 billion in 2025. Although smaller commercially, these institutions are strategically influential because they develop new biomarkers, validate technologies, conduct clinical trials, and shape future standards of care.

Research adoption often precedes routine clinical adoption, making this group particularly important for sequencing, spatial biology, single-cell technologies, advanced imaging, and computational pathology companies.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Precision Oncology Devices Market is geographically divided into the South, Northeast, West and Midwest. Regional performance differs considerably based on cancer incidence, population size, concentration of NCI-designated centers, molecular laboratory capacity, specialist density, academic research infrastructure, pharmaceutical activity, reimbursement mix, health-system consolidation, and availability of advanced pathology and imaging technologies.

The South represents the largest regional market in 2025, while the West is projected to record the fastest growth through 2035. The Northeast remains disproportionately important for high-complexity oncology, clinical trials and academic adoption, while the Midwest combines a large cancer burden with strong integrated health systems and major molecular medicine centers.

South

The South represents an estimated USD 3.74 billion market in 2025, equivalent to approximately 34.5% of U.S. precision oncology device revenue. The region is projected to approach USD 12.50 billion by 2035, implying growth of approximately 12.8% annually.

Using 2025 state cancer projections, the Census-defined South accounts for approximately 802,000 new cancer cases, nearly two-fifths of the national total. The region includes Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, the District of Columbia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas.

Texas is one of the most strategically important precision-oncology markets in the country, with approximately 150,870 new cancer cases estimated in 2025. Houston’s concentration of oncology infrastructure, including globally recognized cancer programs, supports high-volume sequencing, molecular pathology, interventional oncology, clinical trials, and investigational biomarker use. Dallas-Fort Worth, Austin and San Antonio add substantial community and integrated-system demand.

Florida represents another critical market, with approximately 171,960 new cancer cases in 2025, one of the highest state totals nationally. Its large older population supports extensive demand across prostate, lung, breast, colorectal and hematologic cancers. Florida is particularly attractive for molecular testing companies because large oncology networks can aggregate patient volumes across multiple community sites.

North Carolina recorded approximately 71,320 expected cases, while Georgia accounted for around 66,210. Both states combine population growth with expanding academic and integrated healthcare systems. Research clusters in North Carolina also strengthen relationships between precision diagnostics, biotechnology companies, clinical research organizations, and pharmaceutical development.

Virginia, with approximately 50,510 projected cases, and Maryland, with around 37,200, benefit from sophisticated healthcare infrastructure and proximity to federal biomedical research. Tennessee, with approximately 42,750 cases, has strong tertiary oncology and laboratory infrastructure, while South Carolina, Alabama, Louisiana, Kentucky, Mississippi, Arkansas, Oklahoma and West Virginia represent substantial additional demand.

These latter markets also illustrate one of the central commercial challenges in precision oncology: patients may live far from academic molecular centers. Blood-based testing, centralized reference laboratory models, telepathology, cloud-based interpretation, and simplified specimen logistics could therefore have disproportionate value across rural Southern markets.

The South should remain the largest regional revenue pool through 2035 because of population growth, rising cancer prevalence, continued health-system investment, large Medicare populations, expansion of community oncology networks, and increasing molecular testing penetration outside flagship academic centers.

West

The West represents approximately USD 2.65 billion in 2025 and is expected to become an approximately USD 9.70 billion market by 2035, corresponding to an estimated 13.9% CAGR, the fastest of the four U.S. regions.

Approximately 424,000 new cancer cases were expected across Western states in 2025. The region includes California, Washington, Oregon, Nevada, Idaho, Montana, Wyoming, Utah, Arizona, New Mexico, Colorado, Alaska, and Hawaii.

California dominates the region with approximately 199,980 expected cancer cases in 2025. Its importance is substantially greater than its patient volume alone suggests. California combines major NCI-designated cancer centers, genomics companies, medical-device manufacturers, artificial-intelligence developers, biotechnology clusters, venture investment, academic research, and highly sophisticated integrated health systems.

This makes California a leading launch environment for NGS platforms, liquid biopsy, digital pathology, AI-enabled oncology imaging, computational diagnostics, and research technologies that subsequently migrate into broader U.S. practice.

Washington recorded approximately 46,500 projected cancer cases, Arizona around 42,560, Colorado around 29,020, and Oregon approximately 26,980 in 2025. Arizona’s aging and rapidly expanding population makes it particularly important for oncology diagnostic growth, while Colorado, Washington and Utah contain technology-oriented healthcare systems that are receptive to digital and data-intensive cancer workflows.

Nevada, Idaho, Montana, Wyoming, New Mexico, Alaska and Hawaii are smaller individual markets but increase the relevance of distributed precision diagnostics. Centralized sequencing combined with local blood collection, cloud-based pathology, remote subspecialty interpretation, and connected imaging networks can reduce geographic barriers to advanced oncology care.

The West is expected to gain national market share through 2035 because the region is unusually strong in both technology creation and clinical adoption. Artificial intelligence, multi-omic analysis, digital pathology, liquid biopsy, advanced imaging, spatial biology, and cloud-connected diagnostic platforms are all likely to find early commercial adopters within Western health systems.

Northeast

The Northeast represents approximately USD 2.68 billion in 2025 and is projected to reach approximately USD 8.25 billion by 2035, corresponding to an estimated 11.9% CAGR.

Approximately 375,000 new cancers were expected across the Northeast in 2025. The region includes Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey and Pennsylvania.

New York is the dominant state market with approximately 123,430 expected cancer cases in 2025. Its extensive academic hospital ecosystem, large patient population, specialist concentration, clinical-trial infrastructure, and major oncology programs create strong demand across comprehensive genomic profiling, liquid biopsy, digital pathology, molecular imaging and precision-guided biopsy.

Pennsylvania represents another major opportunity, with approximately 90,240 projected cases, supported by large academic and integrated provider networks in Philadelphia, Pittsburgh and surrounding markets. New Jersey accounted for roughly 59,840 expected cases and is commercially important because of the state’s pharmaceutical and biotechnology concentration in addition to patient-care demand.

Massachusetts reported approximately 44,000 expected cases, but its strategic importance considerably exceeds its population share. Boston’s cancer research, genomics, biotechnology, pathology, academic medicine and venture ecosystem makes Massachusetts one of the most influential early-adoption markets for novel precision-oncology technologies.

Connecticut, Maine, New Hampshire, Rhode Island and Vermont provide smaller absolute volumes but participate in interconnected regional referral networks. Digital pathology and centralized genomic testing are particularly relevant because smaller institutions can access subspecialty expertise without reproducing the complete infrastructure of a major academic center.

Northeast procurement is typically evidence intensive. Academic hospitals frequently require analytical validation, prospective clinical data, publication history, pathology and laboratory governance review, cybersecurity assessment, health-economic justification, and evidence that a new technology provides incremental clinical utility. As a result, the region can be more difficult to penetrate commercially but highly influential once adoption occurs.

Midwest

The Midwest represents an estimated USD 1.78 billion precision oncology devices market in 2025 and is projected to reach approximately USD 5.26 billion by 2035, corresponding to an estimated 11.4% CAGR.

The region accounted for approximately 441,000 expected cancer cases in 2025, exceeding the Northeast and West in underlying incidence volume. It includes Ohio, Indiana, Illinois, Michigan, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota.

Illinois recorded approximately 78,870 expected cases, Ohio approximately 77,010, and Michigan about 66,040 in 2025. These states contain large academic centers, community hospital networks and substantial oncology patient populations, supporting demand for molecular profiling and sophisticated pathology systems.

Wisconsin and Missouri accounted for approximately 39,940 and 39,220 expected cases, respectively, while Minnesota represented approximately 37,650. Minnesota is especially important from an industry perspective because of its established medical-technology ecosystem and sophisticated healthcare networks.

Indiana represented approximately 42,150 expected cases, while Iowa, Kansas, Nebraska and the Dakotas collectively provide additional demand. Rural geography creates an important role for regional referral centers, reference laboratories, blood-based testing, remote pathology review and standardized molecular testing pathways.

The Midwest will likely grow more slowly than the technology-intensive West, but its large underlying cancer population provides a durable commercial foundation. Vendors that combine strong clinical performance with practical reagent economics, dependable technical service, laboratory automation, enterprise contracting and local clinical education can build substantial share in the region.

 

Key Market Players

The U.S. Precision Oncology Devices Competitive Landscape is fragmented across sequencing, molecular diagnostics, liquid biopsy, pathology, imaging, AI and clinical decision-support technologies. Unlike conventional device markets, no single manufacturer controls the entire diagnostic journey.

Major sequencing and molecular-platform companies compete on analytical capability, throughput, automation, regulatory status and installed laboratory base. Liquid-biopsy companies compete through clinical evidence, assay sensitivity, pharmaceutical partnerships and payer coverage. Imaging and pathology companies compete through enterprise integration and workflow control. AI companies increasingly compete for the software layer that connects these data sources.

Some of the key participants influencing the U.S. Precision Oncology Devices industry include Illumina; Thermo Fisher Scientific; Roche Diagnostics and Foundation Medicine; Guardant Health; Exact Sciences; Natera; Caris Life Sciences; Tempus AI; QIAGEN; Agilent Technologies; Abbott; Bio-Rad Laboratories; Danaher and Leica Biosystems; Myriad Genetics; NeoGenomics Laboratories; Hologic; GE HealthCare; Siemens Healthineers; Philips; Canon Medical Systems USA; Fujifilm Healthcare Americas; Paige; PathAI; Pacific Biosciences; and SOPHiA GENETICS.

Illumina and Thermo Fisher Scientific remain particularly influential in sequencing infrastructure. Roche and Foundation Medicine have a strong position at the intersection of comprehensive genomic profiling and companion diagnostics. Guardant Health is strategically important in liquid biopsy, therapy selection and blood-based cancer detection. Caris Life Sciences, Tempus AI, Exact Sciences, Natera, NeoGenomics and Myriad participate across different molecular and longitudinal oncology testing categories.

Agilent, Leica Biosystems, Roche and other pathology suppliers remain important because biomarker-driven oncology continues to depend heavily on tissue-based assays. GE HealthCare, Siemens Healthineers, Philips, Canon Medical and Fujifilm contribute imaging and workflow technologies that support tumor characterization, biopsy and disease assessment.

Competitive positioning through 2035 will increasingly depend on clinical evidence rather than technological novelty alone. Companies must demonstrate that their devices improve actionable diagnostic yield, accelerate treatment initiation, reduce repeat procedures, support regulatory-grade biomarker assessment, or lower total diagnostic cost.

Pharmaceutical partnerships will remain another major competitive lever. A device incorporated into companion diagnostic development can acquire strong commercial defensibility because its use becomes linked to treatment selection. Companies capable of supporting global clinical trials while maintaining a strong U.S. regulatory strategy should be positioned particularly well.

Consolidation is likely as larger diagnostics and medtech companies seek access to genomics, liquid biopsy, AI or specialized pathology technologies. At the same time, the pace of biological innovation should continue to create opportunities for smaller companies addressing specific biomarkers, tumor types, workflow bottlenecks or emerging surveillance applications.

 

Recent Developments

Recent developments demonstrate how rapidly the U.S. Precision Oncology Devices Market is moving from exploratory molecular medicine toward regulated routine practice.

In 2024, regulators authorized 76 oncology-related devices, including 27 in vitro diagnostic devices. The year included new comprehensive genomic profiling products, expanded companion diagnostic indications, colorectal screening technologies and liquid-biopsy-related regulatory activity. These approvals strengthened the commercial pathway for regulated molecular oncology devices.

In August 2024, TruSight Oncology Comprehensive received U.S. approval as a comprehensive tumor profiling and companion diagnostic platform. Its ability to analyze hundreds of DNA and RNA targets demonstrated the movement toward highly multiplexed regulated oncology testing rather than sequential single-gene assays.

In November 2024, MI Cancer Seek received approval as an NGS-based tumor profiling device with multiple companion diagnostic applications. Its profile illustrates the growing importance of platforms capable of combining broad genomic characterization with direct therapeutic relevance.

The Guardant Shield blood-based colorectal cancer screening test received U.S. approval in July 2024 for average-risk adults aged 45 years and older. Its authorization was commercially significant because it demonstrated that circulating DNA technologies can move beyond therapy selection into population-scale cancer screening.

Liquid biopsy regulation also advanced through authorization of PGDx elio plasma focus Dx, a high-throughput sequencing-based tumor-profiling test using circulating cell-free nucleic acids. Such developments improve regulatory clarity around blood-based molecular profiling and strengthen confidence in liquid-biopsy device categories.

In 2025, regulatory momentum accelerated further, with more than 90 oncology devices authorized, including 26 IVD devices as well as a substantial number of oncology radiology and imaging technologies.

One strategically important 2025 approval involved the Oncomine Dx Express Test, which uses targeted next-generation sequencing on an integrated sequencing platform and supports tumor profiling together with companion diagnostic applications. Integrated systems of this type could improve the economics of bringing regulated oncology sequencing closer to hospital laboratories.

Companion diagnostic indications also continued expanding across existing platforms during 2025 and 2026 as new targeted therapies entered the market. This creates an important recurring commercial dynamic: once a molecular platform is established, additional biomarker and therapeutic claims can increase its value without requiring a completely new laboratory infrastructure.

The broader precision-oncology infrastructure also continued expanding. In 2026, the U.S. network reached 74 NCI-Designated Cancer Centers, strengthening the institutional base for clinical trials, biomarker research and early technology adoption.

Across the competitive ecosystem, artificial intelligence is increasingly moving from retrospective research toward prospective workflow deployment. Digital pathology algorithms, imaging-risk models, clinical-trial matching systems and molecular interpretation platforms are becoming part of purchasing discussions alongside conventional hardware.

The next stage of development is likely to emphasize integration. Sequencing data, pathology images, radiology, circulating DNA, treatment history and real-world outcomes will increasingly need to operate as a connected information system. Companies that own only one diagnostic data layer may therefore pursue partnerships or acquisitions to improve longitudinal coverage.

 

Conclusion

The U.S. Precision Oncology Devices Market Size & Share is positioned for rapid expansion from approximately USD 10.85 billion in 2025 to USD 35.71 billion by 2035, representing a projected 12.65% CAGR during 2026–2035.

The market’s growth is supported by the scale of U.S. cancer incidence, increasing biomarker-directed treatment, regulatory expansion of companion diagnostics, improving genomic-testing coverage, declining workflow friction around sequencing, rising liquid-biopsy utilization, digital pathology deployment, artificial intelligence, molecular imaging and growing demand for longitudinal cancer monitoring.

Comprehensive genomic profiling remains the largest current device category, but liquid biopsy and MRD-oriented technologies are expected to generate some of the strongest incremental growth. Digital pathology and computational oncology should also become materially more important as hospital networks attempt to increase specialist productivity and integrate molecular, morphologic and clinical data.

The central commercial opportunity is shifting from identifying cancer to characterizing it repeatedly over time. Initial tissue diagnosis may be followed by genomic profiling, therapy selection, liquid biopsy at progression, molecular response assessment and recurrence monitoring. This increases the lifetime diagnostic value associated with each patient and supports recurring device and consumable demand.

Regional opportunity will remain uneven. The South is expected to remain the largest market, supported by approximately 802,000 projected annual cancer cases in 2025, large population centers and expanding oncology networks. The West should deliver the fastest growth, driven by technology creation, venture investment and early adoption. The Northeast will remain disproportionately influential in clinical evidence generation, while the Midwest offers a large, durable patient base and sophisticated integrated health systems.

For manufacturers, success will increasingly depend on workflow economics rather than analytical performance alone. Hospitals will favor technologies that preserve tissue, shorten turnaround time, reduce send-out testing, automate interpretation, improve patient selection, integrate with laboratory and clinical systems, and provide a credible reimbursement pathway.

For investors and strategic buyers, the most attractive opportunities are likely to occur where diagnostic recurrence and strong clinical utility intersect: comprehensive profiling, liquid biopsy, minimal residual disease, digital pathology, AI-enabled biomarker interpretation, molecular imaging, companion diagnostics, and integrated oncology data platforms.

The defining question for the next decade will not be whether precision oncology becomes more important. It will be which device platforms become indispensable enough to sit permanently inside the cancer-care workflow. Companies that demonstrate measurable improvements in therapeutic selection, diagnostic efficiency, recurrence detection and total oncology economics will be best positioned to capture premium growth through 2035.

 

TABLE OF CONTENT

1. U.S. Precision Oncology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Precision Oncology Device and Platform Manufacturers
1.6.2. Molecular Diagnostic Assay and Consumable Suppliers
1.6.3. Hospitals, Comprehensive Cancer Centers and Integrated Delivery Networks
1.6.4. Molecular Diagnostic and Reference Laboratories
1.6.5. Community Oncology Networks and Specialty Cancer Practices
1.6.6. Pharmaceutical, Biotechnology and Clinical Research Organizations
1.6.7. Payers, Regulators and Oncology Clinical Decision-Makers

What this section provides: This section defines the U.S. Precision Oncology Devices Market boundary, study scope, methodology, assumptions, device and diagnostic ecosystem, and stakeholder structure so clients understand precisely how the market is measured, modeled and validated.

2. U.S. Precision Oncology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size & Forecast, 2021–2035 (US$ Billion)
2.8. High-Growth Opportunity Areas
2.8.1. Comprehensive Genomic Profiling
2.8.2. Liquid Biopsy and ctDNA Testing
2.8.3. Minimal Residual Disease Monitoring
2.8.4. Companion Diagnostics
2.8.5. Digital Pathology and AI-Enabled Oncology Diagnostics
2.8.6. Precision Molecular Imaging

What this section provides: This section provides decision-makers with a concise view of market size, historical development, forecast growth, technology direction, competitive intensity and the precision oncology device categories expected to generate the strongest commercial opportunities through 2035.

3. U.S. Precision Oncology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Oncology Diagnostic Burden
3.1.2. Expansion of Biomarker-Directed and Targeted Cancer Therapies
3.1.3. Increasing Adoption of Comprehensive Genomic Profiling
3.1.4. Growth of FDA-Approved Companion Diagnostics
3.1.5. Increasing Clinical Adoption of Liquid Biopsy and ctDNA Testing
3.1.6. Growing Demand for Minimal Residual Disease and Recurrence Monitoring
3.1.7. Expansion of Digital Pathology and AI-Assisted Oncology Diagnostics
3.2. Restraints and Their Impact Analysis
3.2.1. High Cost of Advanced Molecular Diagnostic Platforms
3.2.2. Reimbursement Variability Across Precision Oncology Tests
3.2.3. Limited Clinical Utility Evidence for Emerging Biomarkers
3.2.4. Tumor Tissue Availability and Pre-Analytical Sample Constraints
3.2.5. Molecular Pathology and Bioinformatics Workforce Constraints
3.2.6. High Data Storage, Interpretation and Cybersecurity Requirements
3.3. Opportunities and Their Impact Analysis
3.3.1. Expansion of Blood-Based Cancer Testing
3.3.2. Minimal Residual Disease Testing Across Solid Tumors
3.3.3. Tumor-Agnostic Biomarker Testing
3.3.4. Decentralization of Precision Oncology Testing into Regional Cancer Centers
3.3.5. AI-Based Digital Pathology and Image Biomarker Quantification
3.3.6. Integrated Genomic, Pathology and Imaging Decision Platforms
3.3.7. Pharmaceutical Companion Diagnostic Co-Development
3.4. Challenges and Their Impact Analysis
3.4.1. Clinical and Genomic Data Interoperability
3.4.2. Regulatory Complexity Across Software, IVD and Laboratory Workflows
3.4.3. Standardization of Molecular Testing and Variant Interpretation
3.4.4. Demonstrating Incremental Clinical Utility
3.4.5. Health Equity and Geographic Access to Precision Oncology
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Precision Oncology Clinical Workflow Economics Analysis
3.7. Hospital and Molecular Laboratory Capital Procurement Behavior Analysis
3.8. In-House Testing Versus Reference Laboratory Outsourcing Economics

What this section provides: This section explains the clinical, technological, reimbursement, laboratory and operational forces shaping precision oncology device demand and helps clients evaluate growth catalysts, adoption constraints and execution risks.

4. U.S. Precision Oncology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Healthcare and Laboratory Buyers
4.2.3. Bargaining Power of Technology and Reagent Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Precision Oncology Device and Assay Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization, Cloud Analytics and Connected Oncology
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework for Oncology IVDs, Companion Diagnostics and Software Devices
4.8. CMS Reimbursement and Precision Oncology Coverage Landscape
4.9. CLIA Laboratory Environment and Molecular Testing Requirements
4.10. Import/Export Restrictions, Semiconductor Availability and Tariff Impact
4.11. Government Initiatives, Cancer Research Programs and Precision Medicine Initiatives
4.12. Impact of Escalating Geopolitical and Supply Chain Tensions
4.13. Hospital and Laboratory Value Analysis Committee Decision Framework
4.14. Data Privacy, Cybersecurity and Genomic Information Governance

What this section provides: This section gives clients a comprehensive understanding of regulation, reimbursement, pricing, supply chain, technology adoption, laboratory economics, cybersecurity and healthcare procurement factors influencing the U.S. Precision Oncology Devices Market.

5. U.S. Precision Oncology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Comprehensive Genomic Profiling and NGS Platforms
5.1.2.1. High-Throughput NGS Systems
5.1.2.2. Integrated Sample-to-Answer Sequencing Systems
5.1.2.3. Targeted Oncology Sequencing Panels
5.1.2.4. Whole-Exome and Expanded Genomic Profiling Platforms
5.1.2.5. NGS Reagents, Kits and Device-Linked Consumables
5.1.3. Liquid Biopsy and ctDNA Systems
5.1.3.1. Circulating Tumor DNA Platforms
5.1.3.2. Cell-Free DNA Analysis Systems
5.1.3.3. Circulating Tumor Cell Systems
5.1.3.4. Methylation and Epigenomic Detection Platforms
5.1.3.5. Multimodal Blood-Based Oncology Testing Systems
5.1.4. PCR, Digital PCR and Targeted Molecular Systems
5.1.4.1. Real-Time PCR Systems
5.1.4.2. Digital PCR Systems
5.1.4.3. Multiplex PCR Platforms
5.1.4.4. Targeted Mutation Detection Systems
5.1.5. Digital Pathology, IHC and ISH Platforms
5.1.5.1. Whole-Slide Imaging Systems
5.1.5.2. Immunohistochemistry Platforms
5.1.5.3. In Situ Hybridization Systems
5.1.5.4. AI-Assisted Pathology Analysis Platforms
5.1.5.5. Quantitative Biomarker Imaging Systems
5.1.6. Precision Imaging and Image-Guided Oncology Devices
5.1.6.1. Molecular Imaging Systems
5.1.6.2. AI-Enabled Oncology Imaging Platforms
5.1.6.3. Image-Guided Biopsy Systems
5.1.6.4. Navigation and Robotic Biopsy Platforms
5.1.6.5. Quantitative Tumor Characterization Systems

What this section provides: This section identifies which precision oncology device categories contribute the greatest revenue, where technology substitution is occurring, and which platforms are expected to generate the strongest growth through 2035.

6. U.S. Precision Oncology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Companion Diagnostics and Therapy Selection
6.1.2.1. Targeted Therapy Selection
6.1.2.2. Immunotherapy Biomarker Assessment
6.1.2.3. Tumor-Agnostic Therapy Selection
6.1.2.4. Resistance Mutation Profiling
6.1.3. Early Detection and Risk Stratification
6.1.3.1. Blood-Based Cancer Detection
6.1.3.2. Molecular Risk Assessment
6.1.3.3. Image-Based Cancer Risk Stratification
6.1.3.4. Hereditary and Genomic Risk Integration
6.1.4. Minimal Residual Disease and Recurrence Surveillance
6.1.4.1. Post-Surgical MRD Monitoring
6.1.4.2. Post-Systemic Therapy Surveillance
6.1.4.3. Molecular Recurrence Detection
6.1.4.4. Longitudinal ctDNA Monitoring
6.1.5. Treatment Response and Resistance Monitoring
6.1.5.1. Molecular Treatment Response Assessment
6.1.5.2. Acquired Resistance Detection
6.1.5.3. Clonal Evolution Monitoring
6.1.5.4. Therapy Switching Decision Support
6.1.6. Clinical Trial Enrollment and Biomarker Research
6.1.6.1. Patient Molecular Screening
6.1.6.2. Biomarker-Selected Trial Enrollment
6.1.6.3. Companion Diagnostic Co-Development
6.1.6.4. Translational Oncology Research

What this section provides: This section evaluates precision oncology device demand by clinical use case and helps clients identify applications with the strongest testing frequency, clinical utility, reimbursement relevance and recurring revenue potential.

7. U.S. Precision Oncology Devices Market – By Cancer Type

7.1. Overview
7.1.1. Segment Share Analysis, By Cancer Type, 2025 & 2035 (%)
7.1.2. Lung Cancer
7.1.2.1. Non-Small Cell Lung Cancer
7.1.2.2. Small Cell Lung Cancer
7.1.2.3. Molecular Profiling and Companion Diagnostic Demand
7.1.2.4. Liquid Biopsy and Resistance Monitoring
7.1.3. Breast Cancer
7.1.3.1. Hormone Receptor-Positive Breast Cancer
7.1.3.2. HER2-Positive and HER2-Low Breast Cancer
7.1.3.3. Triple-Negative Breast Cancer
7.1.3.4. Genomic Recurrence and ctDNA Monitoring
7.1.4. Colorectal Cancer
7.1.4.1. RAS/BRAF Molecular Profiling
7.1.4.2. MSI/MMR Testing
7.1.4.3. Blood-Based Detection
7.1.4.4. MRD and Post-Surgical Recurrence Monitoring
7.1.5. Prostate Cancer
7.1.5.1. Genomic Risk Stratification
7.1.5.2. HRR/BRCA Molecular Testing
7.1.5.3. Precision Molecular Imaging
7.1.5.4. Advanced and Metastatic Prostate Cancer Profiling
7.1.6. Hematologic Malignancies
7.1.6.1. Leukemia
7.1.6.2. Lymphoma
7.1.6.3. Multiple Myeloma
7.1.6.4. Molecular and Measurable Residual Disease Testing
7.1.7. Other Solid Tumors
7.1.7.1. Ovarian Cancer
7.1.7.2. Pancreatic Cancer
7.1.7.3. Melanoma
7.1.7.4. Bladder Cancer
7.1.7.5. Brain and Central Nervous System Tumors
7.1.7.6. Liver and Biliary Tract Cancer
7.1.7.7. Kidney Cancer
7.1.7.8. Endometrial and Other Gynecologic Cancers
7.1.7.9. Thyroid Cancer
7.1.7.10. Sarcoma and Rare Molecularly Defined Tumors

What this section provides: This section quantifies precision oncology device demand by cancer type and highlights where biomarker complexity, targeted therapy penetration, testing frequency and molecular surveillance create the strongest commercial opportunity.

8. U.S. Precision Oncology Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Hospitals and Comprehensive Cancer Centers
8.1.2.1. NCI-Designated Cancer Centers
8.1.2.2. Academic Medical Centers
8.1.2.3. Integrated Delivery Networks
8.1.2.4. Regional Tertiary Cancer Centers
8.1.3. Diagnostic and Reference Laboratories
8.1.3.1. National Reference Laboratories
8.1.3.2. Specialty Molecular Oncology Laboratories
8.1.3.3. Hospital-Owned Molecular Laboratories
8.1.3.4. Independent Pathology Laboratories
8.1.4. Community Oncology Networks
8.1.4.1. Independent Oncology Practices
8.1.4.2. Multisite Community Cancer Networks
8.1.4.3. Hospital-Affiliated Community Oncology Practices
8.1.5. Pharmaceutical, Biotechnology and CRO Customers
8.1.5.1. Pharmaceutical Companies
8.1.5.2. Biotechnology Companies
8.1.5.3. Contract Research Organizations
8.1.5.4. Central Clinical Trial Laboratories
8.1.6. Academic and Translational Research Institutes
8.1.6.1. University Research Laboratories
8.1.6.2. Translational Oncology Institutes
8.1.6.3. Government and Nonprofit Cancer Research Centers

What this section provides: This section identifies the principal U.S. customer groups purchasing and using precision oncology technologies and analyzes differences in testing volume, capital budgets, reimbursement exposure, outsourcing behavior and technology adoption.

9. U.S. Precision Oncology Devices Market – By Geography

9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Cancer Incidence and Oncology Infrastructure Analysis
9.1.4. Regional NCI-Designated Cancer Center and Molecular Laboratory Analysis
9.1.5. Regional Precision Oncology Adoption and Testing Penetration
9.1.6. Regional Reimbursement and Payer Dynamics
9.1.7. Regional Laboratory Procurement and Testing Outsourcing Dynamics
9.2. West Region
9.2.1. Regional Overview & Trends
9.2.2. West Region Precision Oncology Device Key Manufacturers, Laboratories and Procurement Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.8. California
9.2.8.1. Overview
9.2.8.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.8.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.8.4. California Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.8.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.9. Washington
9.2.9.1. Overview
9.2.9.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.9.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.9.4. Washington Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.9.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.10. Arizona
9.2.10.1. Overview
9.2.10.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.10.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.10.4. Arizona Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.10.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.11. Colorado
9.2.11.1. Overview
9.2.11.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.11.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.11.4. Colorado Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.11.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.12. Oregon
9.2.12.1. Overview
9.2.12.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.12.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.12.4. Oregon Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.12.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.13. Utah
9.2.13.1. Overview
9.2.13.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.13.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.13.4. Utah Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.13.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.14. Nevada
9.2.14.1. Overview
9.2.14.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.14.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.14.4. Nevada Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.14.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.15. New Mexico
9.2.15.1. Overview
9.2.15.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.15.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.15.4. New Mexico Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.15.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.16. Idaho
9.2.16.1. Overview
9.2.16.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.16.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.16.4. Idaho Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.16.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.17. Montana
9.2.17.1. Overview
9.2.17.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.17.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.17.4. Montana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.17.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.18. Wyoming
9.2.18.1. Overview
9.2.18.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.18.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.18.4. Wyoming Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.18.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.19. Alaska
9.2.19.1. Overview
9.2.19.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.19.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.19.4. Alaska Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.19.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.20. Hawaii
9.2.20.1. Overview
9.2.20.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.20.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.20.4. Hawaii Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.20.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3. Northeast Region
9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Precision Oncology Device Key Manufacturers, Laboratories and Procurement Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.8. New York
9.3.8.1. Overview
9.3.8.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.8.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.8.4. New York Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.8.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.9. Massachusetts
9.3.9.1. Overview
9.3.9.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.9.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.9.4. Massachusetts Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.9.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.10. New Jersey
9.3.10.1. Overview
9.3.10.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.10.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.10.4. New Jersey Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.10.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.11. Pennsylvania
9.3.11.1. Overview
9.3.11.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.11.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.11.4. Pennsylvania Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.11.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.12. Connecticut
9.3.12.1. Overview
9.3.12.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.12.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.12.4. Connecticut Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.12.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.13. Maine
9.3.13.1. Overview
9.3.13.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.13.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.13.4. Maine Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.13.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.14. Vermont
9.3.14.1. Overview
9.3.14.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.14.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.14.4. Vermont Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.14.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.15. New Hampshire
9.3.15.1. Overview
9.3.15.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.15.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.15.4. New Hampshire Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.15.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.16. Rhode Island
9.3.16.1. Overview
9.3.16.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.16.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.16.4. Rhode Island Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.16.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.17. Delaware
9.3.17.1. Overview
9.3.17.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.17.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.17.4. Delaware Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.17.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4. South Region
9.4.1. Regional Overview & Trends
9.4.2. South Region Precision Oncology Device Key Manufacturers, Laboratories and Procurement Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.8. Texas
9.4.8.1. Overview
9.4.8.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.8.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.8.4. Texas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.8.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.9. Florida
9.4.9.1. Overview
9.4.9.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.9.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.9.4. Florida Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.9.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.10. Georgia
9.4.10.1. Overview
9.4.10.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.10.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.10.4. Georgia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.10.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.11. North Carolina
9.4.11.1. Overview
9.4.11.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.11.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.11.4. North Carolina Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.11.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.12. Tennessee
9.4.12.1. Overview
9.4.12.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.12.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.12.4. Tennessee Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.12.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.13. South Carolina
9.4.13.1. Overview
9.4.13.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.13.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.13.4. South Carolina Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.13.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.14. Alabama
9.4.14.1. Overview
9.4.14.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.14.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.14.4. Alabama Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.14.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.15. Mississippi
9.4.15.1. Overview
9.4.15.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.15.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.15.4. Mississippi Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.15.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.16. Louisiana
9.4.16.1. Overview
9.4.16.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.16.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.16.4. Louisiana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.16.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.17. Arkansas
9.4.17.1. Overview
9.4.17.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.17.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.17.4. Arkansas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.17.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.18. Kentucky
9.4.18.1. Overview
9.4.18.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.18.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.18.4. Kentucky Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.18.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.19. Oklahoma
9.4.19.1. Overview
9.4.19.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.19.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.19.4. Oklahoma Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.19.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.20. Virginia
9.4.20.1. Overview
9.4.20.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.20.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.20.4. Virginia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.20.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.21. Maryland
9.4.21.1. Overview
9.4.21.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.21.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.21.4. Maryland Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.21.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.22. West Virginia
9.4.22.1. Overview
9.4.22.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.22.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.22.4. West Virginia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.22.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5. Midwest Region
9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Precision Oncology Device Key Manufacturers, Laboratories and Procurement Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.8. Illinois
9.5.8.1. Overview
9.5.8.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.8.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.8.4. Illinois Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.8.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.9. Ohio
9.5.9.1. Overview
9.5.9.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.9.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.9.4. Ohio Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.9.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.10. Michigan
9.5.10.1. Overview
9.5.10.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.10.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.10.4. Michigan Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.10.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.11. Minnesota
9.5.11.1. Overview
9.5.11.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.11.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.11.4. Minnesota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.11.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.12. Indiana
9.5.12.1. Overview
9.5.12.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.12.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.12.4. Indiana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.12.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.13. Wisconsin
9.5.13.1. Overview
9.5.13.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.13.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.13.4. Wisconsin Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.13.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.14. Missouri
9.5.14.1. Overview
9.5.14.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.14.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.14.4. Missouri Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.14.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.15. Iowa
9.5.15.1. Overview
9.5.15.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.15.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.15.4. Iowa Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.15.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.16. Kansas
9.5.16.1. Overview
9.5.16.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.16.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.16.4. Kansas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.16.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.17. Nebraska
9.5.17.1. Overview
9.5.17.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.17.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.17.4. Nebraska Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.17.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.18. North Dakota
9.5.18.1. Overview
9.5.18.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.18.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.18.4. North Dakota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.18.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.19. South Dakota
9.5.19.1. Overview
9.5.19.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.19.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.19.4. South Dakota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.19.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level precision oncology analysis, enabling clients to identify high-value cancer markets, molecular-testing hubs, NCI-center clusters, liquid-biopsy adoption hotspots, laboratory infrastructure gaps and state-level commercial opportunities across all 50 U.S. states.

10. U.S. Precision Oncology Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Company Positioning Matrix
10.2.1. Leaders
10.2.2. Challengers
10.2.3. Innovators
10.2.4. Emerging Players
10.3. Competitive Benchmarking
10.3.1. Product and Platform Breadth
10.3.2. FDA-Approved Oncology Diagnostics Portfolio
10.3.3. Companion Diagnostic Partnerships
10.3.4. Sequencing and Molecular Testing Installed Base
10.3.5. Liquid Biopsy Capabilities
10.3.6. Digital Pathology and AI Capabilities
10.3.7. U.S. Commercial and Laboratory Network Presence
10.4. Company Profiles
10.4.1. Illumina, Inc.
10.4.2. Thermo Fisher Scientific Inc.
10.4.3. Roche Diagnostics
10.4.4. Foundation Medicine, Inc.
10.4.5. Guardant Health, Inc.
10.4.6. Exact Sciences Corporation
10.4.7. Natera, Inc.
10.4.8. Caris Life Sciences
10.4.9. Tempus AI, Inc.
10.4.10. QIAGEN N.V.
10.4.11. Agilent Technologies, Inc.
10.4.12. Abbott Laboratories
10.4.13. Bio-Rad Laboratories, Inc.
10.4.14. Danaher Corporation / Leica Biosystems
10.4.15. Myriad Genetics, Inc.
10.4.16. NeoGenomics Laboratories, Inc.
10.4.17. Hologic, Inc.
10.4.18. GE HealthCare Technologies Inc.
10.4.19. Siemens Healthineers
10.4.20. Philips Healthcare
10.4.21. Canon Medical Systems USA, Inc.
10.4.22. FUJIFILM Healthcare Americas Corporation
10.4.23. Paige
10.4.24. PathAI, Inc.
10.4.25. Pacific Biosciences of California, Inc.

Note: Each company profile will include company overview, U.S. precision oncology device and diagnostic portfolio, instrument and assay positioning, oncology biomarker strategy, FDA regulatory status, companion diagnostic relationships, U.S. commercialization strategy, clinical evidence, partnerships, acquisitions, financial positioning and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, platform positioning, companion diagnostic capabilities, innovation direction and strategic intelligence on 25 major companies shaping the U.S. Precision Oncology Devices Market.

11. U.S. Precision Oncology Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario
11.2. Disruptive Technologies Impact
11.2.1. High-Sensitivity Liquid Biopsy and ctDNA Platforms
11.2.2. Minimal Residual Disease Testing
11.2.3. Multi-Omics and Integrated Genomic Profiling
11.2.4. AI-Assisted Digital Pathology
11.2.5. Integrated Sample-to-Answer NGS Systems
11.2.6. Precision Molecular Imaging and Radiomics
11.2.7. Spatial Biology and Tumor Microenvironment Analysis
11.2.8. Multimodal Oncology Decision-Support Platforms
11.3. Emerging Business Trends
11.3.1. Transition Toward Longitudinal Molecular Monitoring
11.3.2. Increasing Pharmaceutical–Diagnostic Co-Development
11.3.3. Growth of Decentralized Precision Oncology
11.3.4. Expansion of Enterprise Molecular Diagnostics Contracts
11.3.5. Increasing Consolidation Across Genomics, AI and Pathology
11.4. Business Opportunities for Startups and Existing Players
11.5. Investment Prioritization Matrix
11.6. High-Growth Technology Opportunity Matrix
11.7. U.S. Precision Oncology Devices Market Outlook to 2035

What this section provides: This section prepares clients for disruptive technology shifts, changing testing models, investment opportunities and alternative adoption scenarios likely to shape the U.S. Precision Oncology Devices Market through 2035.

12. U.S. Precision Oncology Devices Market: Strategic Recommendations

12.1. Recommendations for Precision Oncology Device Manufacturers
12.2. Recommendations for Molecular Diagnostics and Genomics Companies
12.3. Recommendations for Hospitals and Comprehensive Cancer Centers
12.4. Recommendations for Diagnostic and Reference Laboratories
12.5. Recommendations for Pharmaceutical and Biotechnology Companies
12.6. Recommendations for Investors and Private Equity Firms
12.7. Recommendations for New Entrants and Startups
12.8. U.S. Go-to-Market Strategy Considerations
12.9. FDA and Reimbursement Strategy Considerations
12.10. Product Positioning and Portfolio Expansion Guidance
12.11. Partnership, Licensing and M&A Opportunity Framework

What this section provides: This section converts market intelligence into actionable strategic recommendations for commercial expansion, platform positioning, reimbursement planning, partnership development, investment prioritization and competitive differentiation.

13. U.S. Precision Oncology Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Data Use Limitation
13.3. Forecasting Limitation
13.4. Legal Disclaimer
13.5. Third-Party Data Disclaimer
13.6. Precision Oncology Device Market Boundary Disclaimer

What this section provides: This section clarifies the report’s scope, market-definition boundaries, data-use terms, forecasting assumptions, third-party information limitations and legal considerations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Precision Oncology Devices Market: Market Definition and Scope
TABLE 3: U.S. Precision Oncology Devices Market: Research Methodology Framework
TABLE 4: U.S. Precision Oncology Devices Market: Key Assumptions
TABLE 5: U.S. Precision Oncology Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Precision Oncology Devices Market: Stakeholder Analysis
TABLE 7: U.S. Precision Oncology Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Precision Oncology Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Precision Oncology Devices Market: Market Attractiveness Index
TABLE 10: U.S. Precision Oncology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Precision Oncology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Precision Oncology Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Precision Oncology Devices Market: High-Growth Opportunity Areas
TABLE 14: U.S. Precision Oncology Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. Precision Oncology Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. Precision Oncology Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. Precision Oncology Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. Precision Oncology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Precision Oncology Devices Market: Precision Oncology Clinical Workflow Economics Matrix
TABLE 20: U.S. Precision Oncology Devices Market: Hospital and Molecular Laboratory Capital Procurement Behavior Matrix
TABLE 21: U.S. Precision Oncology Devices Market: In-House Testing vs. Reference Laboratory Outsourcing Economics
TABLE 22: U.S. Precision Oncology Devices Market: PESTEL Analysis
TABLE 23: U.S. Precision Oncology Devices Market: Porter’s Five Forces Analysis
TABLE 24: U.S. Precision Oncology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 25: U.S. Precision Oncology Devices Market: Value Chain Analysis
TABLE 26: U.S. Precision Oncology Devices Market: Supply Chain Analysis
TABLE 27: U.S. Precision Oncology Devices Market: Digitalization, Cloud Analytics and Connected Oncology Impact
TABLE 28: U.S. Precision Oncology Devices Market: Application & Innovation Landscape
TABLE 29: U.S. Precision Oncology Devices Market: FDA Regulatory Framework Analysis
TABLE 30: U.S. Precision Oncology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 31: U.S. Precision Oncology Devices Market: CLIA Laboratory Environment and Molecular Testing Requirements
TABLE 32: U.S. Precision Oncology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 33: U.S. Precision Oncology Devices Market: Government Initiatives and Precision Medicine Programs
TABLE 34: U.S. Precision Oncology Devices Market: Impact of Escalating Geopolitical and Supply Chain Tensions
TABLE 35: U.S. Precision Oncology Devices Market: Hospital and Laboratory Value Analysis Committee Decision Framework
TABLE 36: U.S. Precision Oncology Devices Market: Data Privacy, Cybersecurity and Genomic Information Governance
TABLE 37: U.S. Precision Oncology Devices Market: Product Category Snapshot, 2025
TABLE 38: Segment Dashboard; Definition and Scope, by Product Category
TABLE 39: U.S. Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 40: U.S. Precision Oncology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 41: U.S. Precision Oncology Devices Market: Comprehensive Genomic Profiling and NGS Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: U.S. Precision Oncology Devices Market: Liquid Biopsy and ctDNA Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Precision Oncology Devices Market: PCR, Digital PCR and Targeted Molecular Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Precision Oncology Devices Market: Digital Pathology, IHC and ISH Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Precision Oncology Devices Market: Precision Imaging and Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Precision Oncology Devices Market: Application Snapshot, 2025
TABLE 47: Segment Dashboard; Definition and Scope, by Application
TABLE 48: U.S. Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 49: U.S. Precision Oncology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 50: U.S. Precision Oncology Devices Market: Companion Diagnostics and Therapy Selection Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Precision Oncology Devices Market: Early Detection and Risk Stratification Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Precision Oncology Devices Market: Minimal Residual Disease and Recurrence Surveillance Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Precision Oncology Devices Market: Treatment Response and Resistance Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Precision Oncology Devices Market: Clinical Trial Enrollment and Biomarker Research Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Precision Oncology Devices Market: Cancer Type Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by Cancer Type
TABLE 57: U.S. Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 58: U.S. Precision Oncology Devices Market: Segment Share Analysis, by Cancer Type, 2025 & 2035 (%)
TABLE 59: U.S. Precision Oncology Devices Market: Lung Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Precision Oncology Devices Market: Breast Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Precision Oncology Devices Market: Colorectal Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Precision Oncology Devices Market: Prostate Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Precision Oncology Devices Market: Hematologic Malignancies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Precision Oncology Devices Market: Other Solid Tumors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Precision Oncology Devices Market: End User Snapshot, 2025
TABLE 66: Segment Dashboard; Definition and Scope, by End User
TABLE 67: U.S. Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 68: U.S. Precision Oncology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 69: U.S. Precision Oncology Devices Market: Hospitals and Comprehensive Cancer Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Precision Oncology Devices Market: Diagnostic and Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Precision Oncology Devices Market: Community Oncology Networks Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Precision Oncology Devices Market: Pharmaceutical, Biotechnology and CRO Customers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Precision Oncology Devices Market: Academic and Translational Research Institutes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Precision Oncology Devices Market: Regional Snapshot, 2025
TABLE 75: Segment Dashboard; Definition and Scope, by Geography
TABLE 76: U.S. Precision Oncology Devices Market, by Geography, 2021–2035 (US$ Billion)
TABLE 77: U.S. Precision Oncology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 78: U.S. Precision Oncology Devices Market: Regional Cancer Incidence and Oncology Infrastructure Analysis
TABLE 79: U.S. Precision Oncology Devices Market: Regional NCI-Designated Cancer Center and Molecular Laboratory Analysis
TABLE 80: U.S. Precision Oncology Devices Market: Regional Precision Oncology Adoption and Testing Penetration
TABLE 81: U.S. Precision Oncology Devices Market: Regional Reimbursement and Payer Dynamics
TABLE 82: U.S. Precision Oncology Devices Market: Regional Laboratory Procurement and Testing Outsourcing Dynamics
TABLE 83: West Region U.S. Precision Oncology Devices Market: Regional Overview and Trends
TABLE 84: West Region U.S. Precision Oncology Devices Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 85: West Region U.S. Precision Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 86: West Region U.S. Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 87: West Region U.S. Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 88: West Region U.S. Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 89: West Region U.S. Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 90: California Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 91: California Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 92: California Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 93: California Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 94: Washington Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 95: Washington Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 96: Washington Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 97: Washington Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 98: Arizona Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 99: Arizona Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 100: Arizona Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 101: Arizona Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 102: Colorado Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 103: Colorado Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 104: Colorado Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 105: Colorado Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 106: Oregon Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 107: Oregon Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 108: Oregon Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 109: Oregon Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 110: Utah Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 111: Utah Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 112: Utah Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 113: Utah Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 114: Nevada Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 115: Nevada Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 116: Nevada Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 117: Nevada Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 118: New Mexico Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 119: New Mexico Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 120: New Mexico Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 121: New Mexico Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 122: Idaho Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 123: Idaho Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 124: Idaho Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 125: Idaho Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 126: Montana Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 127: Montana Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 128: Montana Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 129: Montana Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 130: Wyoming Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 131: Wyoming Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: Wyoming Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 133: Wyoming Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 134: Alaska Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 135: Alaska Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 136: Alaska Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 137: Alaska Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 138: Hawaii Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 139: Hawaii Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 140: Hawaii Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 141: Hawaii Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 142: Northeast Region U.S. Precision Oncology Devices Market: Regional Overview and Trends
TABLE 143: Northeast Region U.S. Precision Oncology Devices Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 144: Northeast Region U.S. Precision Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 145: Northeast Region U.S. Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 146: Northeast Region U.S. Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 147: Northeast Region U.S. Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 148: Northeast Region U.S. Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 149: New York Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 150: New York Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 151: New York Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 152: New York Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 153: Massachusetts Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 154: Massachusetts Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 155: Massachusetts Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 156: Massachusetts Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 157: New Jersey Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 158: New Jersey Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 159: New Jersey Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 160: New Jersey Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 161: Pennsylvania Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 162: Pennsylvania Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 163: Pennsylvania Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 164: Pennsylvania Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 165: Connecticut Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 166: Connecticut Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 167: Connecticut Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 168: Connecticut Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 169: Maine Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 170: Maine Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 171: Maine Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 172: Maine Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 173: Vermont Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 174: Vermont Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 175: Vermont Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 176: Vermont Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 177: New Hampshire Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 178: New Hampshire Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 179: New Hampshire Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 180: New Hampshire Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 181: Rhode Island Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 182: Rhode Island Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 183: Rhode Island Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 184: Rhode Island Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 185: Delaware Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 186: Delaware Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 187: Delaware Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 188: Delaware Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 189: South Region U.S. Precision Oncology Devices Market: Regional Overview and Trends
TABLE 190: South Region U.S. Precision Oncology Devices Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 191: South Region U.S. Precision Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 192: South Region U.S. Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 193: South Region U.S. Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 194: South Region U.S. Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 195: South Region U.S. Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 196: Texas Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 197: Texas Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 198: Texas Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 199: Texas Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 200: Florida Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 201: Florida Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 202: Florida Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 203: Florida Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 204: Georgia Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 205: Georgia Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 206: Georgia Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 207: Georgia Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 208: North Carolina Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 209: North Carolina Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 210: North Carolina Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 211: North Carolina Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 212: Tennessee Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 213: Tennessee Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 214: Tennessee Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 215: Tennessee Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 216: South Carolina Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 217: South Carolina Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 218: South Carolina Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 219: South Carolina Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 220: Alabama Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 221: Alabama Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 222: Alabama Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 223: Alabama Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 224: Mississippi Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 225: Mississippi Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 226: Mississippi Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 227: Mississippi Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 228: Louisiana Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 229: Louisiana Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 230: Louisiana Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 231: Louisiana Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 232: Arkansas Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 233: Arkansas Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 234: Arkansas Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 235: Arkansas Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 236: Kentucky Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 237: Kentucky Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 238: Kentucky Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 239: Kentucky Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 240: Oklahoma Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 241: Oklahoma Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 242: Oklahoma Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 243: Oklahoma Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 244: Virginia Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 245: Virginia Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 246: Virginia Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 247: Virginia Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 248: Maryland Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 249: Maryland Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 250: Maryland Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 251: Maryland Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 252: West Virginia Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 253: West Virginia Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 254: West Virginia Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 255: West Virginia Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 256: Midwest Region U.S. Precision Oncology Devices Market: Regional Overview and Trends
TABLE 257: Midwest Region U.S. Precision Oncology Devices Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 258: Midwest Region U.S. Precision Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 259: Midwest Region U.S. Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 260: Midwest Region U.S. Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 261: Midwest Region U.S. Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 262: Midwest Region U.S. Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 263: Illinois Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 264: Illinois Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 265: Illinois Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 266: Illinois Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 267: Ohio Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 268: Ohio Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 269: Ohio Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 270: Ohio Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 271: Michigan Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 272: Michigan Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 273: Michigan Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 274: Michigan Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 275: Minnesota Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 276: Minnesota Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 277: Minnesota Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 278: Minnesota Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 279: Indiana Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 280: Indiana Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 281: Indiana Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 282: Indiana Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 283: Wisconsin Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 284: Wisconsin Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 285: Wisconsin Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 286: Wisconsin Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 287: Missouri Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 288: Missouri Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 289: Missouri Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 290: Missouri Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 291: Iowa Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 292: Iowa Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 293: Iowa Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 294: Iowa Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 295: Kansas Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 296: Kansas Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 297: Kansas Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 298: Kansas Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 299: Nebraska Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 300: Nebraska Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 301: Nebraska Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 302: Nebraska Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 303: North Dakota Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 304: North Dakota Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 305: North Dakota Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 306: North Dakota Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 307: South Dakota Precision Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 308: South Dakota Precision Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 309: South Dakota Precision Oncology Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 310: South Dakota Precision Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 311: U.S. Precision Oncology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 312: U.S. Precision Oncology Devices Market: Key Company Market Share Analysis, 2025
TABLE 313: U.S. Precision Oncology Devices Market: Company Positioning Matrix
TABLE 314: U.S. Precision Oncology Devices Market: Product and Platform Portfolio Benchmarking
TABLE 315: U.S. Precision Oncology Devices Market: FDA-Approved Oncology Diagnostics Benchmarking
TABLE 316: U.S. Precision Oncology Devices Market: Companion Diagnostic Partnership Benchmarking
TABLE 317: U.S. Precision Oncology Devices Market: Liquid Biopsy Capability Benchmarking
TABLE 318: U.S. Precision Oncology Devices Market: Digital Pathology and AI Capability Benchmarking
TABLE 319: U.S. Precision Oncology Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 320: Illumina, Inc.: Company Profile
TABLE 321: Thermo Fisher Scientific Inc.: Company Profile
TABLE 322: Roche Diagnostics: Company Profile
TABLE 323: Foundation Medicine, Inc.: Company Profile
TABLE 324: Guardant Health, Inc.: Company Profile
TABLE 325: Exact Sciences Corporation: Company Profile
TABLE 326: Natera, Inc.: Company Profile
TABLE 327: Caris Life Sciences: Company Profile
TABLE 328: Tempus AI, Inc.: Company Profile
TABLE 329: QIAGEN N.V.: Company Profile
TABLE 330: Agilent Technologies, Inc.: Company Profile
TABLE 331: Abbott Laboratories: Company Profile
TABLE 332: Bio-Rad Laboratories, Inc.: Company Profile
TABLE 333: Danaher Corporation / Leica Biosystems: Company Profile
TABLE 334: Myriad Genetics, Inc.: Company Profile
TABLE 335: NeoGenomics Laboratories, Inc.: Company Profile
TABLE 336: Hologic, Inc.: Company Profile
TABLE 337: GE HealthCare Technologies Inc.: Company Profile
TABLE 338: Siemens Healthineers: Company Profile
TABLE 339: Philips Healthcare: Company Profile
TABLE 340: Canon Medical Systems USA, Inc.: Company Profile
TABLE 341: FUJIFILM Healthcare Americas Corporation: Company Profile
TABLE 342: Paige: Company Profile
TABLE 343: PathAI, Inc.: Company Profile
TABLE 344: Pacific Biosciences of California, Inc.: Company Profile
TABLE 345: U.S. Precision Oncology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 346: U.S. Precision Oncology Devices Market: Disruptive Technologies Impact Matrix
TABLE 347: U.S. Precision Oncology Devices Market: Emerging Business Trends
TABLE 348: U.S. Precision Oncology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 349: U.S. Precision Oncology Devices Market: Investment Prioritization Matrix
TABLE 350: U.S. Precision Oncology Devices Market: High-Growth Technology Opportunity Matrix
TABLE 351: U.S. Precision Oncology Devices Market: Outlook to 2035
TABLE 352: U.S. Precision Oncology Devices Market: Strategic Recommendations for Precision Oncology Device Manufacturers
TABLE 353: U.S. Precision Oncology Devices Market: Strategic Recommendations for Molecular Diagnostics and Genomics Companies
TABLE 354: U.S. Precision Oncology Devices Market: Strategic Recommendations for Hospitals and Comprehensive Cancer Centers
TABLE 355: U.S. Precision Oncology Devices Market: Strategic Recommendations for Diagnostic and Reference Laboratories
TABLE 356: U.S. Precision Oncology Devices Market: Strategic Recommendations for Pharmaceutical and Biotechnology Companies
TABLE 357: U.S. Precision Oncology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 358: U.S. Precision Oncology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 359: U.S. Precision Oncology Devices Market: U.S. Go-to-Market Strategy Considerations
TABLE 360: U.S. Precision Oncology Devices Market: FDA and Reimbursement Strategy Considerations
TABLE 361: U.S. Precision Oncology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 362: U.S. Precision Oncology Devices Market: Partnership, Licensing and M&A Opportunity Framework
TABLE 363: U.S. Precision Oncology Devices Market: Scope Limitation
TABLE 364: U.S. Precision Oncology Devices Market: Data Use Limitation
TABLE 365: U.S. Precision Oncology Devices Market: Forecasting Limitation
TABLE 366: U.S. Precision Oncology Devices Market: Legal Disclaimer
TABLE 367: U.S. Precision Oncology Devices Market: Third-Party Data Disclaimer
TABLE 368: U.S. Precision Oncology Devices Market: Precision Oncology Device Market Boundary Disclaimer

List of Figures

FIGURE 1: U.S. Precision Oncology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Precision Oncology Clinical Workflow Economics Framework
FIGURE 11: Hospital and Molecular Laboratory Procurement Decision Framework
FIGURE 12: In-House Testing vs. Reference Laboratory Outsourcing Economics
FIGURE 13: U.S. Precision Oncology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 14: U.S. Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 15: U.S. Precision Oncology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 16: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 17: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Comprehensive Genomic Profiling and NGS Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Liquid Biopsy and ctDNA Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: PCR, Digital PCR and Targeted Molecular Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Digital Pathology, IHC and ISH Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Precision Imaging and Image-Guided Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 24: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Companion Diagnostics and Therapy Selection Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Early Detection and Risk Stratification Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Minimal Residual Disease and Recurrence Surveillance Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Treatment Response and Resistance Monitoring Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Clinical Trial Enrollment and Biomarker Research Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Cancer Type Segment Market Share Analysis, 2025 & 2035
FIGURE 31: Cancer Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Lung Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Breast Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Colorectal Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Prostate Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Hematologic Malignancies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Other Solid Tumors Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 39: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Hospitals and Comprehensive Cancer Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Diagnostic and Reference Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Community Oncology Networks Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Pharmaceutical, Biotechnology and CRO Customers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Academic and Translational Research Institutes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: West Region U.S. Precision Oncology Devices Market Share and Leading Players, 2025
FIGURE 48: West Region Market Share Analysis by State, 2025
FIGURE 49: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: California Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Washington Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Arizona Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Colorado Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Oregon Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Utah Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Nevada Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: New Mexico Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Idaho Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Montana Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Wyoming Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Alaska Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Hawaii Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Northeast Region U.S. Precision Oncology Devices Market Share and Leading Players, 2025
FIGURE 64: Northeast Region Market Share Analysis by State, 2025
FIGURE 65: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: New York Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Massachusetts Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: New Jersey Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Pennsylvania Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Connecticut Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Maine Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Vermont Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New Hampshire Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Rhode Island Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Delaware Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: South Region U.S. Precision Oncology Devices Market Share and Leading Players, 2025
FIGURE 77: South Region Market Share Analysis by State, 2025
FIGURE 78: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Texas Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Florida Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Georgia Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: North Carolina Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Tennessee Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: South Carolina Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Alabama Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Mississippi Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Louisiana Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Arkansas Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Kentucky Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Oklahoma Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Virginia Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Maryland Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: West Virginia Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Midwest Region U.S. Precision Oncology Devices Market Share and Leading Players, 2025
FIGURE 95: Midwest Region Market Share Analysis by State, 2025
FIGURE 96: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Illinois Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Ohio Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Michigan Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Minnesota Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Indiana Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Wisconsin Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Missouri Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Iowa Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Kansas Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Nebraska Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: North Dakota Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: South Dakota Precision Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 110: Company Positioning Matrix
FIGURE 111: Key Player Product and Platform Portfolio Benchmarking
FIGURE 112: Companion Diagnostic and Regulatory Positioning Benchmarking
FIGURE 113: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 114: Precision Oncology Device Innovation Roadmap
FIGURE 115: Liquid Biopsy and ctDNA Adoption Roadmap
FIGURE 116: Minimal Residual Disease Technology Opportunity Map
FIGURE 117: Digital Pathology and AI-Enabled Oncology Growth Roadmap
FIGURE 118: Future Market Scenario Analysis, 2026–2035
FIGURE 119: Disruptive Technologies Impact Matrix
FIGURE 120: Emerging Business Trends Matrix
FIGURE 121: Investment Prioritization Matrix
FIGURE 122: High-Growth Technology Opportunity Matrix
FIGURE 123: Strategic Growth Roadmap for U.S. Precision Oncology Device Companies
FIGURE 124: Go-to-Market Strategy Framework
FIGURE 125: FDA and Reimbursement Strategy Framework
FIGURE 126: Product Positioning and Portfolio Expansion Framework
FIGURE 127: Partnership, Licensing and M&A Opportunity Framework
FIGURE 128: Report Scope and Disclaimer Framework